The ENDO 2022 Annual Conference
Atlanta, Georgia, US 11 June 2022 - 14 June 2022
Fezolinetant reduces hot flashes during menopause
The neurokinin-3 receptor antagonist fezolinetant reduced the frequency and severity of menopause-associated vasomotor symptoms (VMS), according to results of the extension arm of the phase III Skylight 2 trial presented at ENDO 2022.
Timing of liquid LT4 intake doesn’t impact bioavailability
Bioavailability studies presented at ENDO 2022 showed that patients with hypothyroidism can safely take the liquid formulations of levothyroxine (LT4) 15 or 30 minutes before meals, without having to worry about food effect on bioavailability.
Growth hormone reduces liver fat, fibro-inflammation in obese/overweight adults with NAFLD
In adults with overweight/obesity and nonalcoholic fatty liver disease (NAFLD), daily administration of growth hormone (GH) reduced hepatic steatosis and improved markers of hepatic inflammation and fibrosis, a study has shown.
Empagliflozin shows promise for chronic SIAD-induced hyponatremia
The sodium-glucose cotransporter 2 inhibitor empagliflozin showed potential as a treatment alternative for hyponatremia due to chronic syndrome of inadequate antidiuresis (SIAD), according to a trial presented at ENDO 2022.
Obese/overweight patients incur 10 percent long-term weight loss with lifestyle management, medication
Individuals who are overweight or obese can achieve an approximately 10 percent weight loss over 3–5 years with the use of anti-obesity medications in addition to lifestyle management, according to a retrospective study presented at ENDO 2022.
Diabetes status may influence long-term survival in metastatic breast cancer
Long-term overall survival (OS) in patients with metastatic breast cancer (MBC) may be influenced by diabetes status, according to a retrospective study presented at ENDO 2022.